



IK-930 (TEAD inhibitor)

Ikena Oncology





IK-930



IK-930 is an oral TEAD inhibitor in phase 1 trials

NCT05228015

NIH U.S. National Library of Medicine

ClinicalTrials.gov

Find Studies ▾

About Studies ▾

Submit Studies ▾

Resources ▾

About Site ▾

[PRS Login](#)

[Home](#) > [Search Results](#) > Study Record Detail

Save this study

Trial record **1 of 1** for: ik-930

[Previous Study](#) | [Return to List](#) | [Next Study](#)

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors



The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. [Know the risks and potential benefits](#) of clinical studies and talk to your health care provider before participating. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT05228015

Recruitment Status ⓘ : Recruiting

First Posted ⓘ : February 8, 2022

Last Update Posted ⓘ : January 26, 2023

See [Contacts and Locations](#)

[View this study on Beta.ClinicalTrials.gov](#)

Sponsor:

Ikena Oncology

Information provided by (Responsible Party):

Ikena Oncology



There are 2 Ikena patents on TEAD inhibitors.

Composition of matter:
WO 2022/120353 A1

Combination therapy:
WO 2022/159986 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(19) World Intellectual Property Organization
International Bureau
(43) International Publication Date
09 June 2022 (09.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/120353 A1

(51) International Patent Classification:
C07D 413/12 (2006.01) C07D 257/02 (2006.01)
A61K 31/42 (2006.01) C07D 305/08 (2006.01)
A61K 31/44 (2006.01) C07D 401/12 (2006.01)
A61P 35/00 (2006.01) C07D 403/04 (2006.01)
C07D 233/64 (2006.01) C07D 403/10 (2006.01)
C07C 311/16 (2006.01) C07D 403/14 (2006.01)
C07D 241/42 (2006.01) C07D 405/14 (2006.01)
C07D 249/06 (2006.01)

(21) International Application Number:
PCT/US2021/072683

(22) International Filing Date:
02 December 2021 (02.12.2021)

(25) Filing Language: English
(26) Publication Language: English

(30) Priority Data:
63/120,298 02 December 2020 (02.12.2020) US
63/120,372 02 December 2020 (02.12.2020) US

(71) Applicant: IKENA ONCOLOGY, INC. [US/US]; 645 SUMMER STREET, SUITE 101, BOSTON, Massachusetts 02210 (US).

(72) Inventors: CASTRO, Alfredo C.; c/o Ikena Oncology, Inc., 645 Summer Street, Suite 101, Boston, Massachusetts 02210 (US). BURKE, Michael; c/o Ikena Oncology, Inc., 645 Summer Street, Suite 101, Boston, Massachusetts 02210 (US).

(74) Agent: REID, Andrea L.C. et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM).

(54) Title: TEAD INHIBITORS AND USES THEREOF

(57) Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

WO 2022/120353 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(19) World Intellectual Property Organization
International Bureau
(43) International Publication Date
28 July 2022 (28.07.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/159986 A1

(51) International Patent Classification:
A61K 31/4468 (2006.01) A61K 31/519 (2006.01)
A61K 31/47 (2006.01) A61K 31/635 (2006.01)
A61K 31/506 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2022/070330

(22) International Filing Date:
25 January 2022 (25.01.2022)

(25) Filing Language: English
(26) Publication Language: English

(30) Priority Data:
63/141,105 25 January 2021 (25.01.2021) US

(71) Applicant: IKENA ONCOLOGY, INC. [US/US]; 645 SUMMER STREET, SUITE 101, BOSTON, MASSACHUSETTS 02210 (US).

(72) Inventors: CASTRO, Alfredo C.; c/o Ikena Oncology, Inc., 645 Summer Street, Suite 101, Boston, Massachusetts 02210 (US). BURKE, Michael; c/o Ikena Oncology, Inc., 645 Summer Street, Suite 101, Boston, Massachusetts 02210 (US). AMIDON, Benjamin; c/o Ikena Oncology, Inc., 645 Summer Street, Suite 101, Boston, Massachusetts 02210 (US). FROSCH, Hyejin; c/o Ikena Oncology, Inc., 645 Summer Street, Suite 101, Boston, Massachusetts 02210 (US).

(74) Agent: REID, Andrea L.C. et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM).

(54) Title: COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER

(57) Abstract: The present invention provides TEAD inhibitors, and methods of use thereof.

WO 2022/159986 A1








Combination patents are typically more revealing because they often include **in vivo data** (with the compound of interest) that provide **many clues**.


No exception here.



Combination patent ('986) describes the in vivo activity of T-A-32 with either an EGFR and/or a MEK inhibitor



Combo patent provides the structure of T-A-32



Interestingly, of the ~207 structures in the composition of matter ('353), T-A-32 is not included (could be redacted, as some of the examples are left blank). Though the SAR in '353 definitely allude to T-A-32.



Does T-A-32 = IK-930 or is it a **decoy compound**?

Decoy compounds! Seen this before (for example, Gilead's GS-5245). So, gotta make sure this is the right compound.



**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

**FORM S-1
REGISTRATION STATEMENT**
*Under
The Securities Act of 1933*

IKENA ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

2836
(Primary Standard Industrial
Classification Code Number)
645 Summer Street, Suite 101
Boston, MA 02210
(857) 273-8343

81-1697316
(I.R.S. Employer
Identification Number)

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Mark Manfredi, Ph.D.
President and Chief Executive Officer
Ikema Oncology, Inc.
645 Summer Street, Suite 101
Boston, MA 02210
(857) 273-8343

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Richard Hoffman, Esq.
Stephanie Richards, Esq.
William D. Collins, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210
(617) 570-1000

Lisa Firenze, Esq.
Craig Hiltz, Esq.
Wilmer Cutler Pickering Hale & Dorr LLP
7 World Trade Center
250 Greenwich Street
New York, NY 10007
(212) 230-8800

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

Smaller Reporting Company

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.

CALCULATION OF REGISTRATION FEE

Title of each Class of Securities to be Registered	Proposed Maximum Aggregate Offering Price(1)(2)	Amount of Registration Fee
Common Stock, par value \$0.001 per share	\$100,000,000	\$10,910

(1) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.

(2) Includes the offering price of shares that the underwriters may purchase pursuant to an option to purchase additional shares.


The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

March 5, 2021:
SEC S-1 filing
has the big
giveaway.

I like SEC filings because
the company cannot lie.





Eureka! SEC S-1 filing has data on IK-930 combo therapies in mice



Tra = trametinib (MEKi); Osi = Osimertinib (EGFRi)



Side-by-side comparison of tumor volumes confirms T-A-32 = IK-930



Dosing checks out as well:


75 mg/kg IK-930

1 mg/kg Tra (MEKi)

2.5 mg/kg Osi (EGFRi)




Therefore, T-A-32 = IK-930



Bonus side note: IK-930 is very similar to VT-103, an oral TEAD inhibitor by Vivace Therapeutics.


Example 121 in WO2019/040380

-CH₂ difference



Disclosed as VT-103 in Tang et al. Mol. Cancer Ther. (2021)

121



N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide



Questions?

Email: victoriacyanide@gmail.com

Twitter: @victoriacyanide

